在COVID-19和慢性血栓栓塞性肺高血压 (CTEPH) 之间,共享的基因和相关的潜在分子联系
Qianqian Li1, Xia Shi2, Yang Tang3
1Geriatrics Department, Hainan Provincial Hospital of Traditional Chinese Medicine, Haikou , 570203, China.
Journal of thrombosis and thrombolysis
|February 1, 2025
概括
这项研究揭示了慢性血栓栓塞性肺高血压 (CTEPH) 和长期COVID之间的共同分子通路,确定了关键基因和免疫细胞调节器. 研究结果表明,这两种疾病都有共同的疾病机制和潜在的治疗点.
科学领域:
- 基因组学就是基因组学.
- 分子生物学分子生物学
- 肺部医学 肺部医学
背景情况:
- 慢性血栓栓塞性肺高血压 (CTEPH) 和COVID-19 (冠状病毒疾病2019) 分享潜在的分子联系.
- 人们对CTEPH和长期COVID之间的相互关系和共同的病原遗传机制的理解仍然不足.
研究的目的:
- 为了确定CTEPH和长期COVID之间的共享分子通路和关键基因.
- 通过分析分子相似性来探索潜在的诊断和治疗策略.
主要方法:
- 对CTEPH和长期COVID队列 (GSE130391,GSE169687) 的RNA测序 (RNA-seq) 数据分析.
- 权重基因共同表达网络分析 (WGCNA) 以确定关键模块基因.
- 不同基因表达分析,枢纽基因鉴定,丰富分析,免疫细胞分析和药物预测.
主要成果:
- 在CTEPH中确定了645 (长期COVID16周),206 (长期COVID24周) 和1,543个差异表达基因 (DEG).
- 发现了234个交叉的关键模块基因和三个枢纽基因 (DNAJA1,NDUFA5,SLC2A14) 具有高分辨能力 (AUC ≥0.7).
- 揭示了免疫调节,氧化应激和代谢功能障碍的共享途径,激活的CD8 T细胞作为关键调节器. 在监管网络中确定了STAT1和hsa-mir-23a-3p,并预测了潜在的治疗方法.
结论:
- 在CTEPH和长期COVID之间解开了关键的分子联系和共享的病原体.
- 突出了免疫调节,氧化应激和代谢功能障碍在这两种情况中的作用.
- 为实验验证和开发用于CTEPH和COVID-19后续的新型诊断和治疗策略提供了基础.
更多相关视频
相关概念视频
Single Nucleotide Polymorphisms-SNPs
13.9K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
13.9K
Genome-wide Association Studies-GWAS
12.4K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
601
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
601
Pulmonary Hypertension: Classification and Pathogenesis
147
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
147
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
131
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
131
Viral Mutations
32.1K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
32.1K


